アナセトラピブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "アナセトラピブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

5doi.org

2^nd place

6^th place

3clinicaltrials.gov

5,225^th place

low place

3nih.gov

4^th place

24^th place

1nature.com

234^th place

363^rd place

1reuters.com

49^th place

67^th place

1ahjonline.com

low place

1nejm.org

2,374^th place

2,486^th place

1medscape.com

719^th place

3,311^th place

1mixonline.jp

low place

4,576^th place

1theheart.org

low place

1ajconline.org

low place

1forbes.com

54^th place

269^th place

1web.archive.org

1^st place

1ox.ac.uk

613^th place

1,897^th place

1lilly.co.jp

low place

ahjonline.com

Bloomfield D, Carlson GL, Sapre A et al. (October 2009). “Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co-administered with atorvastatin in dyslipidemic patients”. Am. Heart J. 157 (2): 352–360. doi:10.1016/j.ahj.2008.09.022. PMID 19185645.

ajconline.org

Gotto AM Jr.,et al. (January 1, 2014). “Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor Anacetrapib in patients with or at high risk for coronary heart disease.”. Am J Cardiol. On line 113 (1): 76–83. doi:10.1056/NEJMoa1009744 2014年11月2日閲覧。.

clinicaltrials.gov

“MK0859 Dose-Ranging Study”. clinicaltrials.gov. 2014年11月2日閲覧。
“Phase III Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (DEFINE)”. ClinicalTrials.gov. U.S. NIH. 2014年11月2日閲覧。
National Institute of Health (January 30, 2012). “REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification”. clinicaltrials.gov. 2014年11月2日閲覧。

doi.org

Gutstein DE, Krishna R, Johns D, et al. (2012). “Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction”. Clinical Pharmacology & Therapeutics 91 (1): 109–122. doi:10.1038/clpt.2011.271.
Bloomfield D, Carlson GL, Sapre A et al. (October 2009). “Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co-administered with atorvastatin in dyslipidemic patients”. Am. Heart J. 157 (2): 352–360. doi:10.1016/j.ahj.2008.09.022. PMID 19185645.
Cannon CP, Dansky HM, Davidson M, et al. (October 2009). “Design of the DEFINE trial: determining the Efficacy and tolerability of CETP Inhibition with AnacEtrapib”. Am. Heart J. 158 (4): 513–519.e3. doi:10.1016/j.ahj.2009.07.028. PMID 19781408 2014年11月2日閲覧。.
Cannon, Christopher, S. Shah et al (November 17, 2010). “Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease”. The New England Journal of Medicine 363 (25): 2406. doi:10.1056/NEJMoa1009744.
Gotto AM Jr.,et al. (January 1, 2014). “Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor Anacetrapib in patients with or at high risk for coronary heart disease.”. Am J Cardiol. On line 113 (1): 76–83. doi:10.1056/NEJMoa1009744 2014年11月2日閲覧。.

forbes.com

Matthew Herper (October 22, 2013). “Merck heart drug runs into a new worry”. Forbes.com. 2014年11月2日閲覧。

lilly.co.jp

“リリー、高リスク動脈硬化性心血管疾患治療薬Evacetrapibの開発を中止” (PDF). 日本イーライリリー (2015年10月15日). 2016年6月19日閲覧。

medscape.com

Antonio M Gotto Jr, Jennifer E Moon (August 2012). “Safety of Inhibition of Cholesteryl Ester Transfer Protein With AnacetrapibThe DEFINE Study”. Expert Rev Cardiovasc Ther.. 2014年11月2日閲覧。

mixonline.jp

“アナセトラピブ　冠動脈性心疾患患者対象に有効性示す　心血管疾患リスク上昇せず” (2011年1月25日). 2014年11月2日閲覧。

nature.com

Gutstein DE, Krishna R, Johns D, et al. (2012). “Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction”. Clinical Pharmacology & Therapeutics 91 (1): 109–122. doi:10.1038/clpt.2011.271.

nejm.org

Cannon, Christopher, S. Shah et al (November 17, 2010). “Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease”. The New England Journal of Medicine 363 (25): 2406. doi:10.1056/NEJMoa1009744.

nih.gov

pubmed.ncbi.nlm.nih.gov

Bloomfield D, Carlson GL, Sapre A et al. (October 2009). “Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co-administered with atorvastatin in dyslipidemic patients”. Am. Heart J. 157 (2): 352–360. doi:10.1016/j.ahj.2008.09.022. PMID 19185645.
Cannon CP, Dansky HM, Davidson M, et al. (October 2009). “Design of the DEFINE trial: determining the Efficacy and tolerability of CETP Inhibition with AnacEtrapib”. Am. Heart J. 158 (4): 513–519.e3. doi:10.1016/j.ahj.2009.07.028. PMID 19781408 2014年11月2日閲覧。.

ncbi.nlm.nih.gov

Cannon CP, Dansky HM, Davidson M, et al. (October 2009). “Design of the DEFINE trial: determining the Efficacy and tolerability of CETP Inhibition with AnacEtrapib”. Am. Heart J. 158 (4): 513–519.e3. doi:10.1016/j.ahj.2009.07.028. PMID 19781408 2014年11月2日閲覧。.

ox.ac.uk

ctsu.ox.ac.uk

“HPS3/TIMI55 – REVEAL trial of Anacetrapib in high-risk vascular patients recruits the target of 30,000 participants”. University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit (2013年9月2日). 2013年12月3日時点のオリジナルよりアーカイブ。2014年11月2日閲覧。

reuters.com

“Merck says will not seek approval of cholesterol treatment”. Reuters. (2017年) 18 October 2017閲覧。

theheart.org

O'Riordan, Michael (November 17, 2010). “DEFINE: Large effects on LDL and HDL cholesterol with CETP inhibitor anacetrapib”. theheart.org. 2014年11月2日閲覧。

web.archive.org

“HPS3/TIMI55 – REVEAL trial of Anacetrapib in high-risk vascular patients recruits the target of 30,000 participants”. University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit (2013年9月2日). 2013年12月3日時点のオリジナルよりアーカイブ。2014年11月2日閲覧。